USA - NASDAQ:MEDP - US58506Q1094 - Common Stock
The current stock price of MEDP is 605.2 USD. In the past month the price increased by 21.82%. In the past year, price increased by 83.27%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.56 | 216.18B | ||
| DHR | DANAHER CORP | 28.92 | 159.69B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 148.65 | 48.49B | ||
| A | AGILENT TECHNOLOGIES INC | 27.16 | 41.97B | ||
| IQV | IQVIA HOLDINGS INC | 19.23 | 37.49B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.07 | 29.55B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 42.07 | 21.39B | ||
| WAT | WATERS CORP | 29.39 | 21.40B | ||
| ILMN | ILLUMINA INC | 24.06 | 15.39B | ||
| TEM | TEMPUS AI INC | N/A | 15.50B | ||
| ICLR | ICON PLC | 13.5 | 13.85B | ||
| RVTY | REVVITY INC | 20.22 | 11.48B |
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 6,000 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
MEDPACE HOLDINGS INC
5375 Medpace Way
Cincinnati OHIO 45227 US
CEO: August J. Troendle
Employees: 5900
Phone: 15135799911
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 6,000 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
The current stock price of MEDP is 605.2 USD. The price increased by 1.44% in the last trading session.
MEDP does not pay a dividend.
MEDP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
MEDP stock is listed on the Nasdaq exchange.
The PE ratio for MEDPACE HOLDINGS INC (MEDP) is 42.32. This is based on the reported non-GAAP earnings per share of 14.3 and the current share price of 605.2 USD.
MEDPACE HOLDINGS INC (MEDP) will report earnings on 2026-02-09, after the market close.
ChartMill assigns a technical rating of 10 / 10 to MEDP. When comparing the yearly performance of all stocks, MEDP is one of the better performing stocks in the market, outperforming 93.15% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to MEDP. MEDP gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months MEDP reported a non-GAAP Earnings per Share(EPS) of 14.3. The EPS increased by 25.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 18.74% | ||
| ROA | 26.61% | ||
| ROE | 242.7% | ||
| Debt/Equity | 0 |
17 analysts have analysed MEDP and the average price target is 433.15 USD. This implies a price decrease of -28.43% is expected in the next year compared to the current price of 605.2.
For the next year, analysts expect an EPS growth of 13.61% and a revenue growth 16.94% for MEDP